


PHARMACEUTICAL 2018

ABBOTT LABORATORIES Rank 16 of 342









PHARMACEUTICAL 2018



ABBOTT LABORATORIES Rank 16 of 342



The relative strengths and weaknesses of ABBOTT LABORATORIES are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABBOTT LABORATORIES compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 76% points. The greatest weakness of ABBOTT LABORATORIES is the variable Other Expenses, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 274%, being 229% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	20,147,000
Cost of Goods Sold	0
Intangible Assets	45,493,000
Liabilities, Current	8,912,000
Liabilities, Non-Current	0
Other Assets	3,003,000
Other Compr. Net Income	1,052,000
Other Expenses	17,094,000
Other Liabilities	0
Other Net Income	1,533,000
Other Revenues	27,390,000
Property and Equipment	7,607,000
Research and Development	2,235,000
Selling, General and Administrative Expense	9,117,000

Output Variable	Value in 1000 USD
Assets	76,250,000
Liabilities	8,912,000
Expenses	28,446,000
Revenues	27,390,000
Stockholders Equity	67,338,000
Net Income	477,000
Comprehensive Net Income	1,003,000
Economic Capital Ratio	274%

